|
Anemia, Hemolytic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV).
|
29851985 |
2018 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis showed that IPTA rs1127354 non-genotype CC, HCV genotype, a baseline HCV RNA level <4 × 10 IU/mL, IL-28B rs12979860 genotype CC, and low liver fibrosis were independent predictors for SVR during the combination therapy.IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the SVR to PEG-IFN plus ribavirin combination therapy in Chinese HCV-infected patients.
|
28723780 |
2017 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C.
|
28198349 |
2017 |
|
Anemia, Hemolytic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Individuals with lower inosine triphosphatase (ITPA) enzyme activity have a reduced likelihood of experiencing hemolytic anemia during hepatitis C virus (HCV) treatment containing ribavirin (RBV).
|
27349952 |
2017 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although genetic variants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by PR, the mechanism sustaining severe anaemia during triple therapy is still unknown.
|
26104535 |
2016 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ITPA genetic variants protect against ribavirin-induced hemolytic anemia and C20orf194 also proved to be protective against thrombocytopenia.
|
27833958 |
2016 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with chronic hepatitis C virus (HCV) infection.
|
26441325 |
2015 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed a meta-analysis of all eligible studies assessing ITPA gene polymorphisms related to RBV-induced hemolytic anemia in HCV-infected patients published in PubMed, Embase and the Cochrane library prior to the end of 2014.
|
26438033 |
2015 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, inosine triphosphatase (ITPA) gene variants were found to be associated with RBV-induced hemolytic anemia, which could affect treatment dose for selected patients.
|
24022240 |
2014 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, genome-wide association studies (GWAS) in patients with chronic hepatitis C virus (HCV) infection have identified two functional single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, that are associated strongly and independently with hemolytic anemia in patients exposed to pegylated-interferon (Peg-IFN) plus ribavirin (RBV) combined therapy.
|
23201294 |
2013 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Published studies have described a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin (RBV)-induced hemolytic anemia in HCV-infected patients receiving pegylated interferon (pegIFN) and RBV.
|
22585729 |
2012 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These tag SNPs are in high linkage disequilibrium with 2 functional variants in the ITPA gene, rs1127354 and rs7270101, that cause ITPase deficiency and protect against ribavirin (RBV)-induced hemolytic anemia (HA). rs1127354 and rs7270101 showed strong independent associations with Pl reduction (p=10(-12), p=10(-7)) and entirely explained the genome-wide significant associations.
|
21703177 |
2012 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
|
22158703 |
2012 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV).
|
21274861 |
2011 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ITPA is a gene on chromosome 20, coding for inosine triphosphatase, and polymorphisms on this gene have been associated with ribavirin-induced hemolytic anemia.
|
22189977 |
2011 |
|
Anemia, Hemolytic
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
|
20547162 |
2010 |
|
Anemia, Hemolytic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
|
20547162 |
2010 |